Liver Fibrosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Liver fibrosis is an ineffective
wound-healing process of the liver in response to repeated and chronic injury
from many etiologies, such as infectious diseases like viral hepatitis,
metabolic derangements (non-alcoholic steatohepatitis), exposure to toxins
(e.g., alcohol liver diseases), or autoimmune diseases (e.g., primary biliary
cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis). The
morphology characteristics of liver fibrosis are the deposition of
extracellular matrix (ECM) produced by myofibroblasts. Myofibroblasts are
absent from the healthy liver, accumulate in the injured liver, and serve as
the principal effector cells of fibrogenesis. Several events are critical for
the pathogenesis of liver fibrosis and its resolution. Damage to hepatocytes
causes inflammatory reactions, which lead to the activation of hepatic stellate
cells (HSCs). HSCs in the normal liver are in a quiescent state and function to
store retinoids and serve as the pericytes for the sinusoidal endothelial
cells.
- The prevalence of liver fibrosis ranges from 3.9% to 7.5% of
the adult population in the USA. The risk of liver fibrosis increased
rapidly with age in men and women in their 40s and 50s, respectively.
Thelansis’s “Liver Fibrosis Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Liver
Fibrosis treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Liver Fibrosis across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Liver Fibrosis Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment